Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
antibody drug conjugates
Pharma
Gilead unfolds Trodelvy triplet's first-line NSCLC data
Gilead argues that the Trodelvy-Keytruda-chemo data support the company's ongoing phase 3 trial for a doublet without chemo.
Angus Liu
Sep 9, 2024 1:45pm
The TROP2 race for supremacy
Aug 16, 2024 9:45am
TROP2 ADCs, Merck-Daiichi, Eisai—Fierce Pharma Asia
Aug 9, 2024 8:25am
Merck, AstraZeneca, Gilead: The race for supremacy in an ADC field
Aug 2, 2024 4:00pm
Enhertu stalls as AZ, Daiichi navigate 'harder yards' for ADC
Jul 25, 2024 11:12am
Daiichi Sankyo closes ADC patent arbitration with $47M win
Jun 28, 2024 10:36am
